

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Rhonan Ford et al.                      Art Unit : 1625  
Serial No. : 10/566,320                              Examiner : Nizal S. Chandrakumar  
Filed : January 26, 2006                              Conf. No. : 3505  
Title : QUINOLINE DERIVATES AND THEIR USE IN THERAPY

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-490US1 / 101140-1P US.

Respectfully submitted,

Date: April 25, 2008

/John T. Kendall/  
John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21908206.doc

**CERTIFICATE OF MAILING BY EFS-WEB FILING**

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: April 25, 2008

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.	
		Filing Date January 26, 2006	Group Art Unit 1625

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/N.C./	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,751,292	06/14/1988	Fox			
	AD	6,949,539	09/27/2005	Alcaraz et al.			
	AE	7,129,246	10/31/2006	Alcaraz et al.			
/N.C./	AF	US2004/0236109	11/25/2004	Van Straten et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/N.C./	AG	BE 650919 A	07/23/1964	Belgium			Abstract	
	AH	DE 1943404 A	12/17/1970	Germany			Abstract	
	AI	EP 0002065 A1	05/30/1979	Europe				
	AJ	EP 0867436 A1	09/30/1998	Europe				
	AK	WO 95/04720	02/16/1995	WIPO				
	AL	WO 99/26927	06/03/1999	WIPO				
	AM	WO 99/29660	06/17/1999	WIPO				
	AN	WO 99/29661	06/17/1999	WIPO				
	AO	WO 00/61569	10/19/2000	WIPO				
	AP	WO 00/73283	12/07/2000	WIPO				
	AQ	WO 2001/037826	05/31/2001	WIPO			Abstract	
	AR	WO 01/94338	12/13/2001	WIPO				
	AS	WO 03/042190	05/22/2003	WIPO				
	AT	WO 03/045313	06/05/2003	WIPO				
/N.C./	AU	WO 2006/059945	06/08/2006	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/N.C./	AV	Accession No. 2003:42109, CAS Registry No. 487064-48-2
Examiner Signature /Nizal Chandrakumar/		Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.	
		Filing Date January 26, 2006	Group Art Unit 1625

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
/N.C./	AW	Agosta et al., "Preparation of 3-Hydroxycyclohexaneacetonitriles", <i>J. Org. Chem.</i> 46:4880-4885 (1981)	
	AX	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155	
	AY	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)	
	AZ	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> ," 13:4047-4050 (2003)	
	AAA	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)	
	ABB	Casy et al., "Synthesis and Pharmacological Evaluation of Some $\beta,\beta$ -Disubstituted Analogs of Acetylcholine", <i>J. Med. Chem.</i> 15(6):642-646 (1972)	
	ACC	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles", <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)	
	ADD	Ferrari et al., "Extracellular ATP Triggers IL-1 $\beta$ Release by Activating the Purinergic P2Z Receptor of Human Macrophages", <i>J. Immunol.</i> 159:1451-1458 (1997)	
	AEE	Ferrari et al., "Purinergic Modulation of Interleukin-1 $\beta$ Release from Microglial Cells Stimulated with Bacterial Endotoxin", <i>J. Exp. Med.</i> 185(3):579-582 (1997)	
	AFF	Fulop et al., "A Versatile Method for the Synthesis of <i>cis</i> -2-aminomethylcyclohexanols", <i>Synthetic Communications</i> 28(12):2303-2309 (1998)	
	AGG	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist", <i>Cytokine</i> 3(3):246-249 (1991)	
	AHH	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ <i>ij</i> ] quinoline as a VLA-4 Antagonist", <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)	
	AII	Kadota et al., "Significance of IL-1 $\beta$ and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)", <i>Clin Exp. Immunol.</i> 103:461-466 (1996)	
	AJJ	Khurana et al., "Clinical aspects of rheumatoid arthritis", <i>Pathophysiology</i> , Volume 12, Issue 3, Abstract (2005)	
	AKK	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)	
	ALL	Leonard et al., "Small Charged Rings. II. The Synthesis of Aziridinium Salts", <i>J. Am. Chem. Soc.</i> 84:4806-4813 (1962)	
	AMM	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)	
	ANN	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)	
	AOO	Miginiac et al., "Activation of Zinc by Trimethylchlorosilane: An Improved Procedure for the Preparation of $\beta$ -Hydroxy Esters from Ethyl Bromoacetate and Aldehydes or Ketones (Reformatsky Reaction)", <i>J. Org. Chem.</i> 52:4796-4798 (1987)	
	APP	Otterness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act</i> 39 (Suppl):109-120 (1993)	

Examiner Signature /Nizal Chandrakumar/	Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.	
		Filing Date January 26, 2006	Group Art Unit 1625

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/N.C./	AQQ	Richards et al., "Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy," <i>Eur. J. of Medic. Chem.</i> , 41:950-969 (2006)
	ARR	Sakito et al., "Interleukin 1 $\beta$ , Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy", <i>Respiration</i> 63:42-48 (1996)
	ASS	STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, 14 April 2002
	ATT	STN International, File REGISTRY, see RN 445032-09-7, 30 August 2002
	AUU	STN International, File CHEMCATS, Accession no. 2001:48444, 14 May 2001, NS18552, 2-Quinolinecarboxamide, N-(tricycle[3.3.1.1 <sup>3,7</sup> ]dec-1-ylmethyl), CAS Registry No. 313688-07-2
	AVV	STN International, File REGISTRY, see RN 401622-10-4, 24 March 2002
	AWW	STN International, File REGISTRY, Registry Copyright 14 July 2006 ACS on STN RN: 892733-99-2, 1 page.
	AXX	STN International, File REGISTRY, Registry Copyright 08 August 2006 ACS on STN RN: 899526-58-0, 1 page.
	AYY	van den Berg, "Lessons from animal models of osteoarthritis, <i>Curr. Opin. Rheumatol.</i> , 13(5): 452-6 (2001)
	AZZ	Whitehead et al., "Diuretics. IV. 6-Chloro-3-substituted 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-Dioxides", <i>J. Org. Chem.</i> 26:2809-2813 (1961)
/N.C./	AAAA	Yu et al., "Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract of <i>Tripterygium wilfordii</i> Hook", <i>Gen. Pharmac.</i> 25(6):1115-1122 (1994)

Examiner Signature /Nizal Chandrakumar/	Date Considered /N.C./
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	